Sufentanil/triazolam sublingual - AcelRx

Drug Profile

Sufentanil/triazolam sublingual - AcelRx

Alternative Names: ARX-03; ARX-F03; sublingual sufentanil/triazolam NanoTab™; triazolam/sufentanil

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator AcelRx Pharmaceuticals
  • Class Benzodiazepines; General anaesthetics; Hypnosedatives; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action GABA A receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain; Sedation

Highest Development Phases

  • Suspended Procedural pain; Sedation

Most Recent Events

  • 30 Jun 2011 Phase II development was completed in USA prior to June 2011
  • 22 Oct 2009 Final efficacy data from a phase II trial in Sedation and Procedural pain released by AcelRx Therapeutics
  • 01 Jun 2009 AcelRx Pharmaceuticals completes a phase II trial in Procedural pain and sedation in USA (NCT00894699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top